Highest-materiality recent filing
Insulet Q2 revenue $802M (+23.5% YoY), beats guidance; EPS $1.37 vs $0.32
Revenue $801.7M, up 23.5% (22.7% constant currency), exceeding guidance of 20-22% constant currency growth.
Insulet voluntary correction for ~7M Omnipod Pods due to cannula tear, up to $50M cost
~7M Pods affected (60% consumed/expired); 24 serious adverse events (hospitalization/DKA), no deaths.
Insulet Q1 revenue $761.7M (+33.9%), beats guidance; raises FY revenue outlook
Q1 revenue $761.7M, up 33.9% YoY (30.1% constant currency), exceeding guidance range of 25-27% constant currency.
On March 12, 2026, Insulet issued a press release regarding a voluntary Medical Device Correction with 18 Serious Adverse Events reported.
Insulet voluntarily corrects Omnipod 5 pods; 18 serious adverse events, up to $40M cost
Voluntary medical device correction for specific lots of Omnipod 5 Pods due to small tear in internal tubing causing under-delivery of insulin.
Insulet Q4 revenue $783.8M (+31%), full year $2.7B (+31%); Board ups buyback by $350M
Q4 revenue $783.8M (+31.2% YoY) exceeded constant-currency guidance of 25-28%.
Insulet Q3 EPS $1.24 beats; revenue up 30% YoY; raises FY guidance
Revenue $706.3M (+29.9% YoY), exceeding 22-25% constant-currency guidance range.
Insulet appoints Flavia Pease as CFO effective Sept 30; expects to exceed Q3 revenue guidance
Ana Chadwick departs as CFO; Flavia Pease, former Charles River Labs CFO, assumes role on Sept 30, 2025.
Insulet Q2 revenue $649M (+32.9%), beats guidance; raises full-year outlook
Revenue $649.1M, up 32.9% YoY (31.3% constant currency), above 26% constant-currency guidance.
Insulet refinances $481.25M term loan at lower rate, redeems 0.375% convertible notes due 2026
Refinanced $481.25M term loans with new term loans at 0.50% lower interest rate margin (2.00% for Term SOFR loans).
Insulet shareholders approve 2025 equity plan adding 7.4M shares; all director nominees elected
2025 Stock Option and Incentive Plan approved (59.9M for, 3.3M against), authorizing 7.4M new shares.
Insulet Q1 revenue up 29% YoY to $569M, raises guidance; new CEO
Revenue $569M (+28.8% YoY) exceeds high end of guidance; Omnipod revenue $554.1M (+28%).
Insulet appoints Ashley McEvoy CEO, expects Q1 revenue above guidance, raising FY outlook
Ashley McEvoy appointed President and CEO effective April 28; succeeds Jim Hollingshead, who resigned from Board.
Issued $450M aggregate principal of 6.50% Senior Notes due 2033; net proceeds ~$444M.
Insulet proposes $450M notes offering to refinance 2026 convertibles; seeks $200M revolver increase
Proposed $450M senior unsecured notes due 2033 in private placement to QIBs and non-US persons.
Insulet FY2024 revenue $2.1B (+22%), beats guidance; GAAP EPS $5.78, adjusted $3.24
FY2024 revenue $2.1B (+22.1% YoY), exceeds constant currency guidance of 20-21%.
Insulet awarded $452M jury verdict against EOFlow for trade secret misappropriation
Jury awarded $170M compensatory and $282M exemplary damages, total $452M, for willful and malicious misappropriation.
Revenue $543.9M (+25.7% YoY); Omnipod $533.6M (+26.4%); U.S. +23.4%, International +36.1%.
Insulet Q2 revenue up 23% to $488.5M, beats guidance; raises FY2024 outlook
Revenue $488.5M (+23.2% YoY), exceeds high end of guidance of 18% constant currency growth.
Insulet refinances $485M term loans, extends maturity to 2031, cuts interest margin by 0.50%
$485M existing term loans replaced with new term loans maturing Aug 2, 2031 (extended from May 2028).
Insulet Q2 preliminary revenue $488M (+23% YoY), raises FY Omnipod guidance to 18-21%
Q2 revenue $488M, up 23% YoY, exceeding guidance of 15-18% constant currency growth.
Insulet Q1 revenue $441.7M (+23% YoY); raises full-year guidance
Q1 revenue $441.7M, +23.3% YoY, above guidance of 17-20% constant currency; Omnipod revenue $433.0M.
Insulet Q4 rev +38% YoY; FY2023 rev $1.7B (+30%), net income $206M, adj EPS $2.75
FY2023 revenue $1.7B (+30% actual, +29.6% constant currency); Q4 revenue +38% YoY.
Insulet Q3 2023 revenue $432.7M (+27% YoY); raises FY revenue guidance to 26-27% growth
Revenue $432.7M (+27% YoY); U.S. Omnipod $320.6M (+34.6%), International $101.4M (+15.2%).
Insulet CFO McMillan resigns effective Oct 20; interim CFO named; guidance reaffirmed
Wayde McMillan resigns as EVP, CFO and Treasurer effective Oct 20, 2023; will join 3M as CFO of its Health Care business.
Complaint filed Aug 3, 2023 in Mass. federal court alleges theft of trade secrets covering Omnipod patch pump design and manufacturing.
Insulet Q2 revenue up 32% to $396.5M; net income $27.3M vs prior year loss
Total revenue $396.5M, +32.4% YoY; Omnipod revenue $380.5M (+33.2%).
Insulet extends Amgen supply agreement through 2028, adds IP license
Amendment 21 extends term to December 31, 2028; parties to negotiate renewal by Jan 1, 2027.
Insulet Q1 revenue $358.1M (+21% YoY); U.S. Omnipod revenue up 49%
Net income $23.8M ($0.34 diluted EPS) vs $27.8M ($0.40) prior year.
the Board appointed Ashley McEvoy as President and Chief Executive Officer of the Company and as a member of the Board as a Class III Director.
James R. Hollingshead, who has agreed with the Board that his employment will cease effective as of April 28, 2025, and resigned from the Board.
Mark Field, who had been serving as the Company’s Senior Vice President and Chief Technology Officer, left the Company, effective March 14, 2025.
Mark Field, Senior Vice President, Chief Technology Officer of Insulet Corporation (the “ Company ”) left the Company to pursue other opportunities, effective March 14, 2025.
Amit Guliani, currently serving as Group Vice President, Software Engineering, will serve as acting Chief Technology Officer, effective immediately.
Lauren Budden, who has been serving as the Company’s Interim CFO and Treasurer, will step down as Interim CFO and Treasurer and continue in her role as Group Vice President, Chief Accounting Officer and Controller.
On March 20, 2024, Insulet Corporation (the “ Company ”) announced the appointment, effective April 22, 2024, of Ana Maria Chadwick to serve as Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer.
On January 18, 2024, the Board of Directors (the "Board") of Insulet Corporation (the "Company") appointed Flavia Pease and Tim Stonesifer as Class II and Class I directors, respectively, effective January 18, 2024.
On January 18, 2024, the Board of Directors (the "Board") of Insulet Corporation (the "Company") appointed Flavia Pease and Tim Stonesifer as Class II and Class I directors, respectively, effective January 18, 2024.
In addition, on January 17, 2024, Corinne H. Nevinny notified the Company of her decision to step down from the Board, effective as of the Company’s 2024 Annual Meeting of Stockholders.
On January 17, 2024, Shacey Petrovic, a member of the Company’s Board of Directors, notified the Company of her decision not to stand for re-election to the Board at the Company’s 2024 Annual Meeting of Stockholders.
On September 29, 2023, Wayde McMillan, the Executive Vice President, Chief Financial Officer and Treasurer of Insulet Corporation (the “ Company ”) informed the Company of his decision to resign from such position, effective October 20, 2023.
Max materiality 0.85 · Median 0.62 · Most common event earnings